Skip to main content

Advertisement

Fig. 6 | Journal of Translational Medicine

Fig. 6

From: Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial

Fig. 6

Pharmacodynamics: mobilization of mature hematopoietic cells. a Balixafortide induces dose-dependent leukocytosis with the same kinetics as observed for CD34+ cells (n = 3–6, mean ± SEM); -fold difference between mature cell mobilization with balixafortide and G-CSF was equivalent to that for CD34+ cells. Differential mobilization of leukocyte subsets was observed, with lower monocyte (b), higher B-cell (c), but similar T-cell (total, CD4+ and CD8+ T-cells, d mobilization after balixafortide vs. G-CSF induced mobilization (n = 3–6, mean ± SEM). G-CSF was administered at the same dose in all groups; the symbol used links mobilization results to a certain balixafortide dosing group

Back to article page